{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:59:09Z","timestamp":1790499549439,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00249","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T05:11:44Z","timestamp":1572930704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa"],"prefix":"10.3389","volume":"6","author":[{"given":"Ahmad","family":"Yatim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9r\u00f4me","family":"Bohelay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grootenboer-Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Prost-Squarcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Le Roux-Villet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/ programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1111\/1346-8138.14601","article-title":"Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab","volume":"46","author":"Ito","year":"2019","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"B13","first-page":"103","article-title":"Bullous pemphigoid associated with a new combination checkpoint inhibitor immunotherapy","volume":"18","author":"Fontecilla","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000489661","article-title":"Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports","volume":"10","author":"Thomsen","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jdcr.2017.06.004","article-title":"Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy","volume":"3","author":"Hirotsu","year":"2017","journal-title":"JAAD Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2019.1619693","article-title":"Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system","volume":"18","author":"Aggarwal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjd.12479","article-title":"Laboratory diagnosis of paraneoplastic pemphigus","volume":"169","author":"Poot","year":"2013","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1172\/JCI115781","article-title":"Human autoantibodies against desmoplakins in paraneoplastic pemphigus","volume":"89","author":"Oursler","year":"1992","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salame","year":"2016","journal-title":"Therapie"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12895-019-0091-7","article-title":"Gluteal hidradenitis suppurativa presenting pemphigus-like findings: case report","volume":"19","author":"Kurihara","year":"2019","journal-title":"BMC Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(04)15539-6","article-title":"Castleman's tumours and production of autoantibody in paraneoplastic pemphigus","volume":"363","author":"Wang","year":"2004","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2005.06599.x","article-title":"Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus","volume":"153","author":"Wang","year":"2005","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T05:11:47Z","timestamp":1572930707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,5]]},"references-count":25,"alternative-id":["10.3389\/fmed.2019.00249"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00249","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,5]]},"article-number":"249"}}